In recent decades, microbial resistance has reached to an incredibly alarming levels,
leading to the development of more potent antimicrobial agents. MRSA (Methicillin-Resistant …

Ceftaroline is a new broad-spectrum parenteral cephalosporin with antibacterial activity
against the prevalent pathogens causing both acute bacterial skin and skin structure …

Ceftaroline fosamil is a novel cephalosporin with broad-spectrum activity against Gram-
positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and …

Ceftaroline fosamil is a fifth-generation cephalosporin with anti-methicillin-resistant
Staphylococcus aureus (MRSA) activity. It has been approved by the EMA and FDA for the …

Ceftaroline is a broad-spectrum cephalosporin currently under clinical investigation for the
treatment of complicated skin and skin-structure infections (cSSSI), including those caused …

Abstract Ceftaroline (PPI 0903, formerly TAK-599), the active metabolite of a N-phosphono
prodrug, ceftaroline fosamil, has been approved by the US Food and Drug Administration for …

Objectives To assess the spectrum and potency of ceftaroline, a novel anti-methicillin-
resistant staphylococcal cephalosporin, against a 2008 surveillance collection of clinical …

Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and
skin-structure infections and community-acquired bacterial pneumonia, including cases with …

Background One of the newest methicillin-resistant Staphylococcus aureus (MRSA)
antibiotics to receive FDA approval is ceftaroline fosamil, a member of a new subclass of …

Abstract Objectives Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a
common cause of complicated skin and skin structure infections (cSSSIs). Increasing …